Innovative Therapeutics in Oncology and Neuroscience
6
Recent Policy Updates in China Continue to be Supportive of Innovation
+
"Price Driven" to "Patient-centric" & "Clinical Value-oriented"
Overall Support for the Industry
NMPA Fostering Innovative
Drug Development
NHSA Providing Better Support
for Innovative Drugs
Biotech designated as one of the
pillar industries in China
14th Five Year Plan targets >10%
annual growth in R&D expenditure
for pharmaceutical industry
Guiding principles for clinical
value-oriented development of
oncology drugs
CDE guideline to accelerate
review for innovative drugs' MAA
"Simplified renewal" rules leading
to milder price cuts and more
clarity on pathways in 2023
Policies leaning towards
innovative drugs' inclusion
Abbreviations: National Medical Products Administration (NMPA), Center for Drug Evaluation (CDE), National Healthcare Security Administration (NHSA), Marketing Authorization Application (MAA).
Sources: NHSA, NMPA, "China biopharma stepping on the global stage" issued on November 16, 2021, McKinsey & Company.
zaiLabView entire presentation